A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This is a phase 1, multicenter, open-label, first-in-human study of YL202 conducted in the
United States and China.
The study will evaluate the safety and tolerability of YL202 in patients with locally
advanced or metastatic epidermal growth factor receptor (EGFR)-mutated NSCLC or hormone
receptor (HR)-positive and HER2-negative BC, which have been heavily treated by standard
treatment.